CN116249710A - 治疗性抗体 - Google Patents
治疗性抗体 Download PDFInfo
- Publication number
- CN116249710A CN116249710A CN202180058009.6A CN202180058009A CN116249710A CN 116249710 A CN116249710 A CN 116249710A CN 202180058009 A CN202180058009 A CN 202180058009A CN 116249710 A CN116249710 A CN 116249710A
- Authority
- CN
- China
- Prior art keywords
- sequence
- seq
- ser
- antibody
- sequence identity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2012331.1 | 2020-08-07 | ||
| GBGB2012331.1A GB202012331D0 (en) | 2020-08-07 | 2020-08-07 | Therapeutic antibodies |
| PCT/GB2021/052043 WO2022029447A1 (en) | 2020-08-07 | 2021-08-06 | Therapeutic antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116249710A true CN116249710A (zh) | 2023-06-09 |
Family
ID=72520053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180058009.6A Pending CN116249710A (zh) | 2020-08-07 | 2021-08-06 | 治疗性抗体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230272097A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4192867A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023540444A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116249710A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021319941A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3186391A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB202012331D0 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022029447A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017189805A1 (en) | 2016-04-27 | 2017-11-02 | Abbvie Inc. | Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies |
| US10093731B2 (en) | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
| JP7671275B2 (ja) | 2019-08-29 | 2025-05-01 | エランコ・ユーエス・インコーポレイテッド | 動物用の抗il31抗体 |
| US20220332837A1 (en) * | 2021-04-08 | 2022-10-20 | Colorado State University Research Foundation | Methods and compositions for ox40 activation in treatment of canine cancer |
| WO2023152486A1 (en) * | 2022-02-09 | 2023-08-17 | Petmedix Ltd | Therapeutic antibodies |
| GB202217978D0 (en) * | 2022-11-30 | 2023-01-11 | Petmedix Ltd | Rodents expressing a common light chain |
| KR20250137204A (ko) | 2022-12-27 | 2025-09-17 | 인베티엑스 인코포레이티드 | 신생아 fc 수용체(fcrn)에 대한 결합이 변경된 폴리펩타이드 및 사용 방법 |
| CN121002059A (zh) | 2023-01-20 | 2025-11-21 | 因外泰克斯公司 | 用于伴侣动物的双特异性结合剂 |
| US20250257142A1 (en) * | 2024-02-13 | 2025-08-14 | Invetx, Inc. | Anti-il-31ra antibodies and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| CA2560889A1 (en) * | 2004-03-23 | 2005-10-13 | Sanjay D. Khare | Monoclonal antibodies specific for human ox40l (cd 134l) |
| GB0525662D0 (en) | 2005-12-16 | 2006-01-25 | Glaxo Group Ltd | Immunoglobulins |
| US7812133B2 (en) * | 2005-12-16 | 2010-10-12 | Genentech, Inc | Anti-OX40L antibodies and methods using same |
| KR102119840B1 (ko) | 2011-07-11 | 2020-06-09 | 아이크노스 사이언스 에스. 아. | Ox40에 결합하는 항체 및 이들의 용도 |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| EA032389B1 (ru) * | 2012-02-14 | 2019-05-31 | Мериал, Инк. | Рекомбинантные поксвирусные векторы, кодирующие и экспрессирующие гликопротеин g вируса бешенства и полипептид oxl, и вакцины, созданные на их основе, используемые в способе вакцинации животных против бешенства |
| GB201316644D0 (en) | 2013-09-19 | 2013-11-06 | Kymab Ltd | Expression vector production & High-Throughput cell screening |
| US10196435B2 (en) | 2013-11-18 | 2019-02-05 | University Of Southern California | OX40L fusion protein for the immunotherapy of tumors of veterinary animals |
| PL3265123T3 (pl) | 2015-03-03 | 2023-03-13 | Kymab Limited | Przeciwciała, zastosowania i sposoby |
| GB2561352B (en) | 2017-04-10 | 2023-01-18 | Genome Res Ltd | Animal models and therapeutic molecules |
| JP7449234B2 (ja) | 2018-03-16 | 2024-03-13 | ゾエティス・サービシーズ・エルエルシー | 獣医学使用のためのインターロイキン31モノクローナル抗体 |
| GB2578867A (en) | 2018-10-09 | 2020-06-03 | Genome Res Ltd | Animal models and therapeutic molecules |
-
2020
- 2020-08-07 GB GBGB2012331.1A patent/GB202012331D0/en not_active Ceased
-
2021
- 2021-08-06 WO PCT/GB2021/052043 patent/WO2022029447A1/en not_active Ceased
- 2021-08-06 AU AU2021319941A patent/AU2021319941A1/en active Pending
- 2021-08-06 EP EP21758732.8A patent/EP4192867A1/en active Pending
- 2021-08-06 US US18/007,314 patent/US20230272097A1/en active Pending
- 2021-08-06 JP JP2023507798A patent/JP2023540444A/ja active Pending
- 2021-08-06 CA CA3186391A patent/CA3186391A1/en active Pending
- 2021-08-06 CN CN202180058009.6A patent/CN116249710A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023540444A (ja) | 2023-09-25 |
| AU2021319941A1 (en) | 2023-02-16 |
| GB202012331D0 (en) | 2020-09-23 |
| WO2022029447A1 (en) | 2022-02-10 |
| EP4192867A1 (en) | 2023-06-14 |
| US20230272097A1 (en) | 2023-08-31 |
| CA3186391A1 (en) | 2022-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230272097A1 (en) | Therapeutic antibodies | |
| JP7061235B2 (ja) | 抗cld18a2ナノ抗体及びその応用 | |
| TWI779479B (zh) | 抗原結合分子類和使用彼等之方法 | |
| JP2022507487A (ja) | Cd25抗体 | |
| KR20180132751A (ko) | Bcma 결합 분자 및 그의 사용 방법 | |
| TWI787594B (zh) | 抗原結合分子和使用彼之方法 | |
| US20240150460A1 (en) | Anti-nkp30 antibody and application thereof | |
| WO2022007543A1 (zh) | 一种抗fgl1抗体及其应用 | |
| CN113621065B (zh) | 靶向4-1bb的全人源抗体及其制备方法和应用 | |
| CN120842422A (zh) | 一种抗CD30和CD16a的双特异性抗体及其应用 | |
| CN120693348A (zh) | 人抗pd-l2抗体及其用途 | |
| US20250340659A1 (en) | Therapeutic antibodies | |
| JP2025534787A (ja) | 抗ヒトインターロイキン36受容体モノクローナル抗体及びその使用 | |
| TWI698643B (zh) | 用於檢測米田堡血型抗原的抗體及其片段、試劑盒及方法 | |
| CN118715244A (zh) | 治疗性抗体 | |
| CN114616245B (zh) | 一种抗cd38的抗体及其用途 | |
| US11274161B2 (en) | Monoclonal antibodies that specifically recognize canine DLA-DR antigen and their uses | |
| CN121108346B (zh) | 抗ly6g6d单域抗体及其制备方法和用途 | |
| JP7844430B2 (ja) | 抗gprc5d抗体に対する抗イディオタイプ抗体 | |
| CN114075284B (zh) | Cd47结合分子及其用途 | |
| US20260035484A1 (en) | Isolated antigen binding protein and use thereof | |
| CN117677637A (zh) | 抗犬cd20抗体 | |
| TW202405013A (zh) | 一種抗原結合蛋白及其應用 | |
| CN117529501A (zh) | 针对抗cd79b抗体的抗独特型抗体 | |
| CN118580351A (zh) | Cd3特异性抗体及其制备方法和相关应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Country or region after: United Kingdom Address after: cambridge Applicant after: Suzhou Service United Kingdom Limited Address before: cambridge Applicant before: Pete Maidi Co.,Ltd. Country or region before: United Kingdom |